Anti-PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) Monoclonal Antibody(Clone: PDL1/2744)
Fig. 1: Western Blot Analysis of HeLa, Raji, MDA231, MCF-7, NIH3T3, Panc-1, cell lysates using PD-L2 Mouse Monoclonal Antibody (PDL1/2744).
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 100 µg |
| Isotype : | Mouse IgG1, kappa |
| Content : | 200 µg/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml. |
| Storage condition : | Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. |
Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, althoµgh produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney sµggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.
ELISA (For coating, order antibody without BSA);,Western Blot (1-2ug/ml),
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
